Most Read Articles
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

04 Mar 2020
At 150-mg doses, oral pregabalin appears to be effective for premature ejaculation, increasing intravaginal ejaculation latency time, a recent study has found.
Pearl Toh, 19 Mar 2020
The lower 0.25 mg/kg dose of the thrombolytic tenecteplase may be sufficient for reperfusion of blocked vessels prior to thrombectomy in patients with ischaemic stroke due to large-vessel occlusion compared with the 0.4 mg/kg dose, according to the EXTEND-IA TNK* Part 2 study presented at the ISC 2020 Meeting.
Roshini Claire Anthony, 6 days ago

The eicosapeptide nerinetide did not improve outcomes in patients with large vessel occlusion-related acute ischaemic stroke who underwent endovascular thrombectomy (EVT). However, patients not treated with alteplase appeared to derive some benefit, results from the multinational ESCAPE-NA1* trial showed.

Vedolizumab does not promote malignancies in IBD patients

08 Jan 2020

Use of vedolizumab for inflammatory bowel disease (IBD) does not contribute to an increased incidence of malignancies, with data from the GEMINI LTS study showing that the rate is similar in groups of patients who received the 4- and 8-weekly infusion regimens.

The current analysis included 1,785 IBD patients (mean age, 39.5 years; 49 percent female) with ≥1 year of follow-up after vedolizumab initiation. Of these, 1,034 had Crohn’s disease (CD) and 751 had ulcerative colitis (UC).  

In 5,670 patient‐years of included vedolizumab exposure, 31 patients (mean age, 51.2 years; 45 percent female) developed malignancies, including 17 with CD and 14 with UC.

Prior use of anti‐TNFα therapy in the group that developed malignancies was documented in 65 percent of CD patients and 57 percent of UC patients; the corresponding proportions in the LTS study were 62 percent and 43 percent.

Researchers indirectly standardized the number of patients experiencing malignancies in the LTS study against the number expected using age- and sex-specific rates in IBD patients from Optum's Clinformatics Data Mart (CDM) database and found that the numbers did not significantly differ (31 vs 29; ratio of observed to expected events, 1.08, 95 percent confidence interval [CI], 0.73–1.53; p=0.71). The most common sites of malignancies were renal and bladder (n=6), lower gastrointestinal (GI) tract (n=5), and respiratory tract (n=4).

In the postmarketing setting, 293 patients reported 299 malignancies (including malignancies within 1 year after vedolizumab initiation) in about 208,050 patient-years of vedolizumab exposure. Lower GI malignancies were most common (n=59).

Despite the presence of limitations, the existing data revealed no evidence of any significant increase in incidence of malignancy in patients with IBD receiving vedolizumab, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

04 Mar 2020
At 150-mg doses, oral pregabalin appears to be effective for premature ejaculation, increasing intravaginal ejaculation latency time, a recent study has found.
Pearl Toh, 19 Mar 2020
The lower 0.25 mg/kg dose of the thrombolytic tenecteplase may be sufficient for reperfusion of blocked vessels prior to thrombectomy in patients with ischaemic stroke due to large-vessel occlusion compared with the 0.4 mg/kg dose, according to the EXTEND-IA TNK* Part 2 study presented at the ISC 2020 Meeting.
Roshini Claire Anthony, 6 days ago

The eicosapeptide nerinetide did not improve outcomes in patients with large vessel occlusion-related acute ischaemic stroke who underwent endovascular thrombectomy (EVT). However, patients not treated with alteplase appeared to derive some benefit, results from the multinational ESCAPE-NA1* trial showed.